CD274 and nonpapillary renal cell carcinoma: KEYNOTE-426 [7] investigated the combination of pembrolizumab with axitinib in the first-line setting in patients with metastatic ccRCC, this combination demonstrated improved OS and PFS regardless of the International Metastatic Database Consortium (IMDC) risk group and PD-L1 status compared to sunitinib.